BofA Securities Downgrades Edwards Lifesciences (EW) to Neutral

Nephron Downgrades Edwards Lifesciences (EW) to Hold

Nephron analyst Chris Pasquale downgraded Edwards Lifesciences (NYSE: EW) from Buy to Hold.

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $86.95 yesterday.

Edwards Lifesciences (EW) PT Lowered to $73 at Piper Sandler

Piper Sandler analyst Adam Maeder lowered the price target on Edwards Lifesciences (NYSE: EW) to $73.00 (from $88.00) while maintaining a Neutral rating.

The analyst commented, "Tonight, EW announced disappointing Q2 results, which stemmed from TAVR growth below management and Street... More

TD Cowen Downgrades Edwards Lifesciences (EW) to Hold

TD Cowen analyst Joshua Jennings downgraded Edwards Lifesciences (NYSE: EW) from Buy to Hold with a price target of $70.00 (from $100.00).

The analyst comments "We are downgrading EW to Hold as we are now forecasting HSD revenue growth in 2024 and 2025 due to... More

Edwards Lifesciences (EW) PT Lowered to $85 at Mizuho

(Updated - July 25, 2024 6:52 AM EDT)

Mizuho analyst Anthony Petrone lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $105.00) while maintaining a Outperform rating.

The analyst commented: "EW posted a $95mn/$0.01 headline beat; however, its core global TAVR segment was... More

Edwards Lifesciences (EW) PT Lowered to $85 at RBC Capital

RBC Capital analyst Shagun Singh lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $101.00) while maintaining a Outperform rating.

The analyst comments "EW delivered Q2'24 results missing sales expectations and lowering 2024 operational revenue growth outlook to 8-10%... More

Edwards Lifesciences (EW) PT Lowered to $90 at Wells Fargo

Wells Fargo analyst Lawrence Biegelsen lowered the price target on Edwards Lifesciences (NYSE: EW) to $90.00 (from $99.00) while maintaining a Overweight rating.... More

Edwards Lifesciences (EW) PT Lowered to $77 at Canaccord Genuity

(Updated - July 25, 2024 6:24 AM EDT)

Canaccord Genuity analyst William Plovanic lowered the price target on Edwards Lifesciences (NYSE: EW) to $77.00 (from $85.00) while maintaining a Hold rating.

The analyst commented: " Edwards reported a top-line Q2 miss, with adjusted revenue of $1,632.3M (+6.7% Y/Y, +7.9% Y/Y CC), coming in below our $1,672.3M estimate, and consensus estimate of $1,654.8M. On the bottom line, EW reported adjusted EPS of $0.70 (including $0.04 from a lower tax rate), compared to our $0.69 estimate.... More

Baird Downgrades Edwards Lifesciences (EW) to Neutral

Baird analyst David Rescott downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Neutral with a price target of $70.00 (from $102.00).

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $86.95 yesterday.

Edwards Lifesciences (EW) PT Lowered to $76 at Evercore ISI

Evercore ISI analyst Vijay Kumar lowered the price target on Edwards Lifesciences (NYSE: EW) to $76.00 (from $91.00) while maintaining a In Line rating.

The analyst comments "Thesis Update: This was tough call for EWthe rev miss, low quality EPS (~5c aid from discrete... More

Truist Securities Downgrades Edwards Lifesciences (EW) to Hold

Truist Securities analyst Richard Newitter downgraded Edwards Lifesciences (NYSE: EW) from Buy to Hold with a price target of $82.00 (from $110.00).

The analyst comments: "We D/G EW to HOLD (vs. BUY) on a lower '24-'25 rev growth & EPS... More

Edwards Lifesciences (EW) PT Lowered to $90 at UBS

UBS analyst Danielle Antalffy lowered the price target on Edwards Lifesciences (NYSE: EW) to $90.00 (from $95.00) while maintaining a Neutral rating.... More

Edwards Lifesciences (EW) PT Lowered to $70 at Stifel

Stifel analyst Rick Wise lowered the price target on Edwards Lifesciences (NYSE: EW) to $70.00 (from $85.00) while maintaining a Hold rating.... More

JPMorgan Downgrades Edwards Lifesciences (EW) to Neutral

JPMorgan analyst Robbie Marcus downgraded Edwards Lifesciences (NYSE: EW) from Overweight to Neutral with a price target of $72.00 (from $105.00).

The analyst comments: "Edwards provided a disappointing update after the close on Wednesday as the announced tuck-ins of JenaValve and Endotronix were overshadowed by a... More

After-hours movers: Chipotle Mexican Grill, Ford, IBM, Edwards Lifesciences, and more

After-Hours Stock Movers:

Chipotle Mexican Grill (NYSE: CMG) climbed 3% after it said comparable restaurant sales increased 11.1% in the second quarter. The fast casual Mexican restaurant chain also reported strong quarterly profits.

Ford Motor (NYSE:... More

Edwards Lifesciences (EW) Tops Q2 EPS by 1c; offers guidance

(Updated - July 24, 2024 5:10 PM EDT)

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.65 billion.

GUIDANCE

The company expects Q3 sales of $1.56... More

Edwards Lifesciences (EW) Reports Acquisitions of JenaValve and Endotronix

Edwards Lifesciences (NYSE: EW) today announced investments that reflect the companys deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. JenaValve presented positive results of its U.S.... More

TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $100.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst commented, "As announced by BSX today, Acurate's US IDE trial results will be presented at ACC in March 2025. Previously, we thought these... More